GSK makes checkpoint progress as PD-1, TIM3 programs advance

With GSK’s Jemperli meeting the primary endpoint in a Phase II non-inferiority study against Keytruda, the pharma has gotten a needed win for a PD-1 inhibitor that could be an essential piece in its strategy to expand its checkpoint inhibitor portfolio. 

GlaxoSmithKline plc (NYSE:GSK) said Jemperli dostarlimab plus chemotherapy met the primary objective response rate (ORR) endpoint in the Phase II PERLA study, though no data were reported. The head-to-head trial evaluated chemotherapy plus Jemperli or Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) to treat first-line non-small cell lung cancer (NSCLC)...